White matter changes in patients with friedreich ataxia after treatment with erythropoietin

J Neuroimaging. 2014 Sep-Oct;24(5):504-8. doi: 10.1111/jon.12050. Epub 2013 Sep 9.

Abstract

Background and purpose: Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients.

Methods: Nine patients with Friedreich ataxia underwent Diffusion Tensor Imaging (DTI) before and after EPO treatment. Tract-based spatial statistics was used for longitudinal comparison.

Results: We detected widespread longitudinal increase in fractional anisotropy and axial diffusivity (D||) in cerebral hemispheres bilaterally (P < .05, corrected), while no changes were observed within the cerebellum, medulla oblongata, and pons.

Conclusions: To the best of our knowledge, this is the first DTI study to investigate the effects of EPO in a neurodegenerative disease. Anatomically, the diffusivity changes appear disease unspecific, and their biological underpinnings deserve further study.

Keywords: Diffusion-tensor imaging; erythropoietin, Fri-edreich ataxia; neurodegeneration; tract-based spatial statistics; white matter.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adolescent
  • Adult
  • Diffusion Tensor Imaging / methods*
  • Erythropoietin / therapeutic use*
  • Female
  • Friedreich Ataxia / drug therapy*
  • Friedreich Ataxia / pathology*
  • Humans
  • Male
  • Middle Aged
  • Neuroprotective Agents / therapeutic use
  • Treatment Outcome
  • White Matter / drug effects
  • White Matter / pathology*
  • Young Adult

Substances

  • Neuroprotective Agents
  • Erythropoietin